NICE Suspends Breyanzi’s Appraisal for R/R NHL
On Tuesday, November 9, NICE reported that Breyanzi’s (BMS’s CD19 CAR-T) clinical and cost-effectiveness appraisal was ‘suspended’ (website). Below, Celltelligence provides insights on the importance and potential causes for Breyanzi’s suspended appraisal in the UK.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.